SCHEMBL11605385

SCHEMBL11605385

COC(=O)c1ccc(OC)nc1OC

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.71
POLB P06746 1/20 0.71
RAB9A P51151 2/20 0.56
NPC1 O15118 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.54
HPGD P15428 2/20 0.54
TSHR P16473 2/20 0.54
HSD17B10 Q99714 2/20 0.54
ALDH1A1 P00352 3/20 0.52
HTT P42858 1/20 0.52
NNMT P40261 1/20 0.50
PDCD1 Q15116 1/20 0.49
CD274 Q9NZQ7 1/20 0.49
KDM4E B2RXH2 1/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31214246 0.84 TDP1 (0.51) TDP1POLBRAB9ANPC1SMN1; SMN2
SCHEMBL426998 0.84 TDP1 (0.50) TDP1POLBRAB9ANPC1SMN1; SMN2
SCHEMBL29859234 0.83 TDP1 (1.00) TDP1POLBRAB9ANPC1SMN1; SMN2
SCHEMBL198490 0.83 TDP1 (1.00) TDP1POLBRAB9ANPC1SMN1; SMN2
SCHEMBL8443874 0.83 POLB (0.73) TDP1POLBRAB9ANPC1SMN1; SMN2
SCHEMBL31141991 0.83 POLB (0.73) TDP1POLBRAB9ANPC1SMN1; SMN2
SCHEMBL6409775 0.83 POLB (0.63) TDP1POLBRAB9ANPC1SMN1; SMN2
SCHEMBL5793016 0.82 POLB (0.61) TDP1POLBRAB9ANPC1SMN1; SMN2
SCHEMBL2027363 0.81 PDCD1 (0.52) TDP1POLBRAB9ANPC1SMN1; SMN2
SCHEMBL21041119 0.81 NNMT (0.69) TDP1POLBRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461183-B2 PPAR agonist compounds, preparation and uses GENFIT (FR) 2013-06-11 US disclosed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP disclosed
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES GENFIT (FR) 2011-08-11 US disclosed
US-4089960-A Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine carboxamides CIBA-GEIGY CORPORATION (US) 1978-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES PPARD, PPARA, PPARG TDP1 4011/4885POLB 2900/4885RAB9A 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.